Crohn's Disease (CD) Treatment Market Report 2026

The crohn's disease (cd) treatment market size has grown steadily in recent years. It will grow from $12.32 billion in 2025 to $12.88 billion in 2026 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing inflammatory bowel disease prevalence, limitations of conventional corticosteroids, hospital-centered disease management, delayed diagnosis rates, reliance on immunomodulators.

The crohn's disease (cd) treatment market size is expected to see strong growth in the next few years. It will grow to $16.01 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in biologics development, growth of precision medicine, expanding patient awareness, improved diagnostic techniques, increased specialty gastroenterology care. Major trends in the forecast period include rising use of biologic therapies, expansion of targeted small molecule drugs, increased focus on long-term disease remission, growth of personalized treatment approaches, integration of combination therapy regimens.

The growing prevalence of inflammatory bowel diseases is expected to drive the growth of the Crohn’s disease (CD) treatment market in the coming years. Inflammatory bowel disease (IBD) refers to a group of chronic inflammatory conditions that primarily affect the gastrointestinal tract. Treatment for Crohn’s disease helps relieve symptoms, reduce inflammation, promote remission, and improve the overall quality of life for individuals living with chronic inflammatory bowel disease. For example, in September 2023, the United States National Library of Medicine, a US-based medical library, reported that in Canada the incidence of inflammatory bowel diseases was estimated at 30 per 100,000 person-years in 2023, with projections indicating a steady annual increase of around 0.58 percent. As of 2023, the prevalence of IBD in Canada reached approximately 825 per 100,000 people, with forecasts suggesting this could rise to 1.1 percent of the population by 2035. Therefore, the rising prevalence of inflammatory bowel diseases is contributing to the growth of the Crohn’s disease treatment market.

Major companies operating in the Crohn’s disease treatment market are increasingly focused on developing advanced technologies, such as non-invasive biomarker-based diagnostic platforms, to improve disease detection, enhance monitoring accuracy, and support personalized treatment decisions. Non-invasive diagnostic technologies for Crohn’s disease involve analyzing biological samples without the need for invasive procedures, enabling earlier detection of inflammation, improved monitoring of disease activity, and a better overall patient experience. For instance, in March 2023, the IRR Chemistry Hub, a Scotland-based interdisciplinary research center, developed IBDSENSE, a fluorescence-based technology designed to improve the diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease. This platform measures the enzyme activity of Granzyme B in patient biosamples, providing a patient-friendly and non-invasive method to assess disease progression and guide treatment choices.

In June 2023, Merck & Co. Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. Through this acquisition, Merck aims to strengthen its portfolio of drugs for immunological and inflammatory conditions. Prometheus Biosciences is a US-based biotechnology company engaged in the development of treatments for inflammatory diseases, with particular expertise in Crohn’s disease and inflammatory bowel disease therapies.

Major companies operating in the crohn's disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann‑La Roche.

North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn's disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crohn's disease (cd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the crohn's disease treatment market by increasing costs of imported biologic drugs, active pharmaceutical ingredients, and injectable formulations. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported biologics, while Asia-Pacific faces higher drug procurement costs. These tariffs are increasing treatment expenses. However, they are also encouraging local manufacturing of biologics and biosimilars.

The crohn's disease (cd) treatment market research report is one of a series of new reports that provides crohn's disease (cd) treatment market statistics, including crohn's disease (cd) treatment industry global market size, regional shares, competitors with a crohn's disease (cd) treatment market share, detailed crohn's disease (cd) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the crohn's disease (cd) treatment industry. This crohn's disease (cd) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Crohn’s disease (CD) is an inflammatory bowel disease that leads to inflammation and swelling of tissues within the digestive tract. Treatment for Crohn’s disease involves a range of approaches, therapies, medications, and medical interventions aimed at managing symptoms and preventing or controlling complications associated with this chronic inflammatory condition.

The primary drug types used in the treatment of Crohn’s disease include antibiotics, aminosalicylates, corticosteroids, immunomodulators, and other drug categories. Antibiotics are medications used to treat bacterial infections by eliminating bacteria or inhibiting their growth and reproduction. These treatments are administered through oral and injectable routes and are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.